Prospects for anti-neoplastic therapies based on telomere biology

Current Cancer Drug Targets

Volumn 2, Issue 1, 2002, Pages 1-17

  Stewart, Sheila A ^a,b   Hahn, William C ^a,b,c  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; NUCLEOPROTEIN;

APOPTOSIS; CANCER THERAPY; CELL DIVISION; CELL IMMORTALIZATION; CELL SURVIVAL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENETIC STABILITY; HUMAN; HUMAN CELL; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SENESCENCE; SOMATIC CELL; SYNTHESIS; TELOMERE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; TELOMERASE; TELOMERE;

EID: 0036285348     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023334015     Document Type: Review

References (184)

1. Telomerase, cell immortality, and cancer
2. The hallmarks of cancer
3. Genetic instabilities in human cancers
4. A critical role for telomeres in suppressing and facilitating carcinogenesis
5. Telomerase in human development and cancer
6. Telomerase activation, cellular immortalization and cancer
7. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes
8. Conservation of the human telomere sequence (TTAGGG)n among vertebrates
9. An overhanging 3′ terminus is a conserved feature of telomeres
10. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening
11. The terminal DNA structure of mammalian chromosomes
12. Normal human chromosomes have long G-rich telomeric overhangs at one end
13. Mammalian telomeres end in a large duplex loop
14. Telomeric localization of TRF2, a novel human telobox protein
15. Human telomeres contain two distinct myb-related proteins, TRF1 and TRF2
16. A human telomeric protein
17. Control of telomere length by the human telomeric protein TRF1
18. TRF2 protects human telomeres from end-to-end fusions
19. Potl, the putative telomere end-binding protein in fission yeast and humans
20. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres
21. Tankyrase promotes telomere elongation in human cells
22. Identification of human Rap1: Implications for telomere evolution
23. The stability of broken ends of chromosomes in Zea mays
24. Healing of broken linear dicentric chromosomes in yeast
25. In vivo alteration of telomere sequences and senescence caused by mutated tetrahymena telomerase RNAs
26. Inhibition of telomerase limits the growth of human cancer cells
27. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2
28. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening
29. Telomere states and cell fates
30. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon
31. Origin of concatemeric T7 DNA
32. The telomere terminal transferase of tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity
33. The RNA component of human telomerase
34. An alternative pathway for yeast telomere maintenance rescues est1-senescence
35. Telomere shortening tumor formation by mouse cells lacking telomerase RNA
36. A telomeric sequence in the RNA of tetrahymena telomerase required for telomere repeat synthesis
37. Telomerase RNA template mutations reveal sequence-specific requirements for the activation and repression of telomerase action at telomeres
38. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation
39. A box H/ACA small nucleolar rna-like domain at the human telomerase RNA 3′ end
40. Dyskeratosis congenita in all its forms
41. A telomerase component is defective in the human disease dyskeratosis congenita
42. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita
43. Reversing time: Origin of telomerase
44. Reverse transcriptase motifs in the catalytic subunit of telomerase
45. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells
46. The catalytic subunit of yeast telomerase
47. Polymerization defects within human telomerase are distinct from telomerase RNA and TEP1 Binding
48. Reconstitution of Human telomerase activity in vitro
49. Human telomerase activation requires two independent between telomerase reverse transcriptase
50. RNA Binding Domain of Telomerase Reverse Transcriptase
51. Human telomerase contains two cooperating telomerase RNA molecules
52. Functional multimerization of the human telomerase reverse transcriptase
53. Functional requirement of p23 and Hsp90 in telomerase complexes
54. Reconstitution of Human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT
55. A mammalian telomerase-associated protein
56. Identification of two RNA-binding proteins associated with human telomerase RNA
57. Purification of tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme
58. Euplotes telomerase contains an la motif protein produced by apparent translational frameshifting
59. Purification of telomerase from euplotes aediculatus: Requirement of a primer 3′ overhang
60. Telomerase-associated protein TEP1 is not essential for telomerase activity or telomere length maintenance in vivo
61. Tetrahymena proteins p80 and p95 are not core telomerase components
62. Telomerase biochemistry and regulation
63. Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes
64. Specific association of human telomerase activity with immortal cells and cancer
65. A survey of telomerase activity in human cancer
66. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes
67. Telomerase activity in human ovarian carcinoma
68. Telomerase activity in normal leukocytes and in hematologic malignancies
69. The serial cultivation of human diploid cell strains
70. Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames
71. Defining the molecular mechanisms of human cell immortalization
72. Role of the retinoblastoma protein in the pathogenesis of human cancer
73. p53, the cellular gatekeeper for growth and division
74. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity
75. Can the ends justify the means? Telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells
76. The telomere hypothesis of cellular aging
77. Telomeres shorten during ageing of human fibroblasts
78. Telomere reduction in human colorectal carcinoma and with ageing
79. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues
80. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization
81. Telomerase catalytic subunit homologs from fission yeast and human
82. Human telomerase contains evolutionarily conserved catalytic and structural subunits
83. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types
84. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas
85. Extension of life-span by introduction of telomerase into normal human cells
86. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span
87. Human keratinocytes that express hTERT and also evade a p16ink4a-enforced lifespan limit become immortal while retaining normal growth and differentiation characteristics
88. Human endothelial cell life extension by telomerase expression
89. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype
90. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase
91. Both Rb/p161NK4a inactivation and telomerase activity are required to immortalize human epithelial cells
92. Immortalization of human CD8(+) T cell clones by ectopic expression of telomerase reverse transcriptase
93. Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8(+) T lymphocyte immortalization
94. Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions
95. Restoration of telomeres in human papillomavirus-immortalized human anogenital epithelial cells
96. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization
97. Telomerase activity is sufficient to allow transformed cells to escape from crisis
98. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts
99. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes
100. Telomerase is controlled by protein kinase calpha in human breast cancer cells
101. Regulation of the hTERT telomerase catalytic subunit by the c-Ab1 tyrosine kinase
102. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit
103. Cutting edge: Telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation
104. Human naive and memory T lymphocytes differ in telomeric length and replicative potential
105. Regulation of telomerase RNA template expression in human T lymphocyte development and activation
106. Telomeres in the haemopoietic system
107. Telomerase is up-regulated in human germinal center B cells in vivo and can be re-expressed in memory B cells activated in vitro
108. Telomerase regulation during entry into the cell cycle in normal human T cells
109. Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridization
110. Frequent amplification of the telomerase reverse transcriptase gene in human tumors
111. Direct activation of TERT transcription by c-Myc
112. Myc activates telomerase
113. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT)
114. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation
115. Identification of Mad as a repressor of the human telomerase (hTERT) gene
116. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1
117. Estrogen activates telomerase
118. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells
119. Telomerase activation by the E6 gene product of human papillomavirus type 16
120. The human papillomavirus type 16 E6 and E7 oncoproteins dissociate cellular telomerase activity from the maintenance of telomere length
121. The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene
122. Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells
123. The human telomerase catalytic subunit hTERT: Organization of the gene and characterization of the promoter
124. Creation of human tumor cells with defined genetic elements
125. Formation of functional tissue from transplanted adrenocortical cells expressing telomerase reverse transcriptase
126. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
127. A genetically tractable model of human glioma formation
128. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes
129. Fibroblast immortality is a prerequisite for transformation by EJ C-HA-Ras oncogene
130. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis
131. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis
132. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice
133. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans
134. Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ
135. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma
136. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)
137. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues
138. Telomere elongation in immortal human cells without detectable telomerase activity
139. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines
140. Telomere maintenance by recombination in human cells
141. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body
142. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway
143. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells
144. Telomere maintenance by telomerase and by recombination can coexist in human cells
145. Inhibition of telomerase by 2′-0-(2- methoxyethyl) RNA oligomers: Effect of length, phosphorothioate substitution and time inside cells
146. Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation
147. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis
148. Inhibition of human telomerase activity by peptide nucleic acids
149. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
150. Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent, FuGENE6, in HeLa cells
151. Inhibition of human telomerase in immortal human cells leads to progessive telomere shortening and cell death
152. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas
153. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA
154. The therapeutic potential of ribozymes
155. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells
156. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase
157. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines
158. The effects of nucleoside analogs on telomerase and telomeres in tetrahymena
159. Inhibition of human telomerase by 7-deaza-2′-deoxyguanosine nucleoside triphosphate analogs: Potent inhibition by 6-thio-7-deaza-2′-deoxyguanosine 5′-triphosphate
160. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells
161. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability
162. Telomerase RNA mutations in Saccharomyces cerevisiae alter telomerase action and reveal nonprocessivity in vivo and in vitro
163. Molecular targeting of cancer: Telomeres as targets
164. The beta subunit of oxytricha telomere-binding protein promotes G-quartet formation by telomeric DNA
165. Ethidium derivatives bind ao G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes
166. The development of telomerase inhibitors: The G-quartet approach
167. Characterization of a G-quartet formation reaction promoted by the beta-subunit of the oxytricha telomere-binding protein
168. Telomerase as a potential molecular target to study G-quartet phosphorothioates
169. Inhibition of telomerase by G-quartet DNA structures
170. Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells
171. Methylation of the human telomerase gene CpG Island
172. Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the bax gene to cancers
173. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters
174. FADD gene therapy using the human telomerase catalytic subunit (hTERT) gene promoter to restrict induction of apoptosis to tumors in vitro and in vivo
175. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter
176. Use of transcriptional regulatory sequences of telomerase (Hter And Htert) for selective killing of cancer cells
177. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
178. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
179. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
180. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes
181. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase
182. Short telomeres result in organismal hypersensitivity to ionizing radiation in mammals
183. Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation
184. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology